Korea Investment CORP Trims Stock Position in Humana Inc. (NYSE:HUM)

Korea Investment CORP decreased its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 34.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,663 shares of the insurance provider's stock after selling 31,247 shares during the period. Korea Investment CORP's holdings in Humana were worth $14,883,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Humana in the third quarter worth approximately $404,000. CreativeOne Wealth LLC purchased a new stake in Humana in the third quarter worth $208,000. Public Sector Pension Investment Board lifted its position in shares of Humana by 13.0% during the third quarter. Public Sector Pension Investment Board now owns 5,222 shares of the insurance provider's stock worth $1,654,000 after purchasing an additional 600 shares during the last quarter. PDT Partners LLC boosted its stake in shares of Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider's stock valued at $1,286,000 after purchasing an additional 2,660 shares during the period. Finally, Paloma Partners Management Co grew its holdings in shares of Humana by 33.7% in the third quarter. Paloma Partners Management Co now owns 853 shares of the insurance provider's stock worth $270,000 after purchasing an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Up 0.2 %

Shares of HUM traded up $0.46 during mid-day trading on Wednesday, hitting $265.20. 1,117,196 shares of the company traded hands, compared to its average volume of 1,753,514. The company has a market capitalization of $32.01 billion, a PE ratio of 26.65, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a 50 day moving average of $269.37 and a 200 day moving average of $272.67. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is 35.58%.

Analyst Ratings Changes

Several research firms have issued reports on HUM. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Barclays increased their price objective on Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. decreased their target price on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a report on Wednesday, January 15th. Eighteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.